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Summary
Autoimmune polyendocrinopathy syndrome type 1
(APS1) is characterized by autoimmune destruction of
endocrine tissues and chronic mucocutaneous candidiasis.
Type 1 diabetes (T1D) affects 12–25% of patients with
APS1, and the prediction of whether this complication
will affect an individual is not currently possible. How-
ever, alleles of a variable number tandem repeat (VNTR)
5′ of the insulin gene are known to influence the develop-
ment of T1D in the general, non-APS1 population. There-
fore, we investigated the prevalence of these IDDM2
alleles in British Caucasian patients with APS1. The study
employed genotyping of 33 patients with APS1 for the
HphI polymorphism that is in tight linkage disequilibrium
with the insulin gene VNTR alleles. Thirty-three patients
with APS1 were studied, the mean age was 23.5 years and
24% have T1D. Six of eight (75%) APS1 patients with
T1D were homozygous for the class I INS VNTR (suscep-
tibility) allele, compared with eight of 25 (32%) of APS1
patients without T1D (P = 0.042). Our data suggest an
association between the development of T1D and
homozygosity for the T1D susceptibility class IINS
VNTR allele in patients with APS1.
Introduction
The autoimmune polyendocrinopathy type 1 syndrome
(APS1 or APECED) is an autosomal recessive, monogenic
form of human autoimmunity characterized by autoimmune
destruction of multiple endocrine organs and defective
cell-mediated immunity (Ahonen, 1985). It is a rare con-
dition, with an estimated prevalence of two to three cases
per million in the UK population (Pearce & Cheetham, 2001).
The cardinal features of APS1 are chronic mucocutaneous
candidiasis, autoimmune hypoparathyroidism and primary
adrenal failure. In addition, a variety of other auto-
immune manifestations occur, of which type 1 diabetes
(T1D) is one of the commonest (Hung et al., 1963; Kenny
& Holliday, 1964; Arulanantham et al., 1979; Neufeld
et al., 1981; Ahonen et al., 1990). APS1 is caused by a
variety of different mutations in the autoimmune regula-
tor (AIRE) gene on chromosome 21q22 (Finnish-German
APECED Consortium, 1997; Nagamine et al., 1997).
There is generally thought to be no genotype–phenotype
correlation, although the spectrum of APS1 manifesta-
tions found in Iranian Jews appears to be milder (Zlo-
togora & Shapiro, 1992). We have previously reported
that the commonest AIRE mutation in Caucasians with
APS1 from the UK population is 964del13 (71% of
mutant alleles) (Pearce et al., 1998), whereas in the Finnish
population the mutation R257* predominates (85% of
mutant alleles) (Finnish-German APECED Consortium,
1997; Nagamine et al., 1997). Unlike other autoimmune
polyendocrinopathy syndromes, there are no known human
leucocyte antigen (HLA) associations with the cardinal
manifestations of APS1. However, Gylling et al. (2000)
have suggested that HLA DQβ1*0602 may be associated
with protection against the development of T1D in an
APS1 population. AIRE is expressed in immunologically
relevant tissues (Heino et al., 1999) and evidence from
knockout mice reveals that it plays a role in the expression
of self-antigen within the thymus and thus in the appro-
priate negative selection of potentially autoreactive T
cells. Therefore, the absence of functional AIRE, as seen
in APS1, affects the establishment of self-tolerance, lead-
ing to the autoimmune destruction of end organs (Ander-
son et al., 2002; Ramsey et al., 2002; Liston et al., 2003).
APS1 most frequently manifests in childhood, with
additional disease components developing throughout
life. However, at the present time, prediction of new man-
ifestations or complications of APS1 is problematic
(Pearce & Cheetham, 2001; Pearce & Leech, 2004). In a
large series of Finnish patients the prevalence of T1D was
12–18% (Ahonen et al., 1990; Tuomi et al., 1996), this
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compares with a prevalence of 0.4% for T1D in a non-
APS1 UK population.
APS1 can be considered to represent a monogenic
human ‘model’ of autoimmune disease, where auto-
immune diseases occur at much higher frequency than in
the non-APS1 population. By homology to animal models
of disease, it is probable that modifier loci play a role in
the development of the individual autoimmune diseases,
thus explaining the lack of obvious AIRE-1 genotype–
phenotype correlation in humans. Given the high risk of
additional autoimmune manifestations in this condition,
these modifier loci that influence the susceptibility to
certain autoimmune manifestations may be easily detected
in APS1 patient cohorts (Gylling et al., 2000). In the
non-APS1 population, T1D is inherited as a complex
trait (Wandstrat & Wakeland, 2001). The strongest
genetic variants that influence T1D susceptibility are the
major histocompatibility complex (MHC) class II genes
(IDDM1), the lymphoid tyrosine phosphatase (PTPN22),
the cytotoxic T-lymphocyte antigen 4 (CTLA4) (Ueda
et al., 2003; Bottini et al., 2004) and the insulin gene pro-
moter (IDDM2) (Bennett et al., 1995). Of the MHC class
II genes, HLA DQB and in particular residue 57, deter-
mines susceptibility to (or protection from) T1D (Todd
et al., 1987). HLA DQB1*0201 and *0302 alleles are
predisposing alleles for T1D in a non-APS1 population,
with compound heterozygosity for these alleles being
present in 30% of patients with T1D. In addition a non-
aspartate residue at position 57 of the DQβ-chain on
either DQB allele is present in 98% of patients with TID
(Badenhoop et al., 1995). The 5′ polymorphic region of
the insulin gene (INS), located on chromosome 11p15.5,
consists of a variable number of tandem repeats (VNTR)
and determines susceptibility to T1D (IDDM2) (Bennett
et al., 1995; Bennett & Todd, 1996). This INS gene poly-
morphism can be divided into three classes depending on
the number of repeats: the class III allele of the INS gene
is dominantly protective for T1D, whereas homozygosity
for the class I allele predisposes to T1D (relative risk 1.9–
5.0) (Bennett et al., 1995). Given the higher prevalence of
T1D in patients with APS1 (about 20% vs. 0.4% in the
background population), these modifier loci may be easier
to identify than in a non-APS1 population. Ward et al.
(1999) previously reported two siblings with APS1 who
were discordant for T1D, and suggested that INS alleles
may have role in the development of the T1D associated
with APS1. Therefore, the aim of this study was to
define the relationship between these IDDM2 polymor-
phisms and the presence of T1D in a larger group of
patients with APS1.
Patients and methods
Patients
Thirty-three British Caucasian patients with APS1 were
studied; the mean age was 24.2 years, the range is 9–56
years, with 24 males and nine females. These patients
were members of 28 unrelated kindreds with subjects 5
and 27, 9 and 13, 10 and 12, 11 and 15 and 19 and 21,
being full siblings (Table 1). Diagnosis in the proband of
a family was based on the presence of at least two of
three cardinal features, chronic mucocutaneous candi-
diasis (CMC), primary hypoparathyroidism and primary
adrenal failure. In a sibling of an index case, one of the
cardinal features was sufficient for the diagnosis of APS1.
Twenty-seven (82%) of the patients have CMC, 29 (88%)
have hypoparathyroidism and 23 (70%) have primary
adrenal failure. Other features include alopecia, hepatitis,
enteropathy and hypogonadism. Eight (24%) patients
have diabetes. DNA was obtained from these patients
for AIRE-1 mutational analysis, HLA allelotyping and
IDDM2 polymorphism analysis. Local ethical approval
was obtained for the extraction of DNA and subsequent
analysis from these patients.
DNA extraction and AIRE mutational analysis
DNA was extracted from whole blood using the Nucleon
BACC2 kit (Anachem, Bedfordshire, UK). All patients
were screened for the two common AIRE mutations by
polymerase chain reaction (PCR) and restriction enzyme
digest. For the 964del13 mutation, primers encompassing
exon 8 were used followed by digest with BsrB1. For the
Finnish major mutation, R257*, primers encompassing
exon 6 were used followed by digest with Taq1. The prod-
ucts were resolved on a 1.5% agarose gel (Pearce et al.,
1998).
IDDM2 polymorphism analysis
This was examined utilizing the HphI polymorphism,
which is effectively in complete linkage disequilibrium
(0.002 recombination rate) with the INS VNTR alleles
(Bennett et al., 1995; Bennett & Todd, 1996). Genomic
DNA was amplified by PCR using oligonucleotide prim-
ers to produce a 441-bp fragment. The primer sequences
were 5′-TCC AGG ACA GGC TGC ATC AG-3′ and 5′-
AGC AAT GGG CGG TTG GCT CA-3′. PCR was per-
formed with 250 ng of DNA, 200 µm of dNTPs, 0.75 mm
of MgCl2, 1 × PCR buffer and 1 U of Taq DNA poly-
merase (Life Technologies Inc., Paisley, UK) in a final volume
of 50 µL. After an initial denaturation at 94 °C for 5 min,
28 cycles of PCR amplification were performed, with each
cycle consisting of 1 min at 94 °C, 1 min at 58 °C and 1
min at 72 °C. The PCR product was digested overnight at
37 °C with the restriction enzyme HphI. This yields frag-
ments of 240 and 160 bp in patients homozygous for the
A allele; 280 and 160 bp in patients homozygous for the
B allele and 160, 240 and 280 bp in heterozygotes. These
fragments were resolved by electrophoresis on a 2% aga-
rose gel. The A allele at the Hph1 polymorphism is carried
on the same haplotype as the class I VNTR alleles, and the
B allele is on the class III VNTR haplotype. Because of the
near complete disequilibrium between alleles of the Hph1
SNP and the VNTR genotypes, the A and B alleles have
been considered as containing the same information as
INS VNTR genotypes for the purposes of our study.
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Determination of HLA type
The presence or absence of a non-aspartate 57 allele (HLA
class II DQB1 *0201, 0302, 0501 and 0604) or the ‘pro-
tective’ HLA class II DQB1*0602 was determined by low
resolution HLA typing using primers supplied by the
Blood Transfusion Service in Newcastle upon Tyne.
Further high-resolution typing was carried out by the Blood
Transfusion Service. HLA typing on an additional seven
patients was performed using an HLA-DQB high resolu-
tion kit from Protrans (Quest Biomedical, Solihull, UK).
Statistical analysis
All genotypes were in Hardy–Weinberg equilibrium.
Using one-sided Fisher’s exact test, 2 × 2 contingency tables
were analysed. Odds ratios and confidence intervals (CI)
were calculated according to Woolf’s method.
Results
AIRE-1 mutation screening
The 964del13 mutation was present in 31 of our 33 UK
patients (94%), accounting for 46 of the 66 alleles (70%).
This is in accordance with our previously reported find-
ings (Pearce et al., 1998). In addition, three of 36 patients
were heterozygous for the Finnish major mutation
R257*, accounting for three of 66 alleles (4.5%).
IDDM2 genotypes and diabetes
Overall, we found that eight of the 33 (24%) APS1 sub-
jects had T1D (Table 1). Of these eight, six (75%) were
homozygous for the Hph1 A allele, which is in tight link-
age disequilibrium with the T1D susceptibility class I
VNTR. In comparison, only eight of 25 (32%) APS1
Table 1. Clinical manifestations, AIRE and INS genotypes of APS1 subjects
Sex/age at 
assessment
Type 1 
diabetesa
Other disease
manifestationsb
INS Hph1
genotypec
Non-Asp57 
allele/DQB0602 AIRE mutationd
1 M 10 Y HP,M,H AA Y 964del13 + Un
2 M 15 Y HP,AD,CMC,C AA Un 964del13 + Un
3 M 20 Y HP,AD,CMC,A,T AA Un 964del13x2
4 M 24 Y HP,AD,CMC,GF AB N 964del13x2
5 M 33 (sib of 27)e Y HP,AD,CMC,A AA N 964del13x2
6 M 37 Y AD,CMC,M,RCA,OC BB Y × 10del + L28P
7 M 41 Y HP,AD,CMC,GF,M,K,PA AA N 964del13x2
8 F 52e Y HP,AD,CMC,GF AA Un 964del13 + Un
9 M 9 (sib of 13) N HP,AD,CMC AA Y 964del13 + Un
10 F 10 (sib of 12) N HP,CMC AB N 964del13 + Un
11 M 10 (sib of 15) N HP AB Y 964del13x2
12 M 13 (sib of 10) N CMC,H AB Un 964del13 + Un
13 M 12 (sib of 9) N HP,AD,CMC,M AA Un 964del13 + Un
14 F 13 N HP,CMC AA 0602 964del13x2
15 F 13 (sib of 11) N HP,CMC,M,K,H,P AB Un 964del13x2
16 M 14 N HP,AD AB N 964del13x2
17 F 15 N HP,AD,CMC,H BB N 964del13x2
18 M 15 N HP,H,Ch AA Un 964del13 + Un
19 F 16 (sib of 21) N HP BB N 964del13 + R15L
20 M 17 N HP,AD,CMC,GF,M AB N 964del13 + Un
21 M 19 (sib of 19) N HP,AD,CMC,GF,H BB 0602 964del13 + R15L
22 M 20 N HP,AD,CMC,GF,M AA N 964del13x2
23 M 23 N HP,AD AA Y 964del13 + R257a
24 F 26 N HP,AD,CMC,M,T AB Un 964del13x2
25 F 26 N HP,AD,CMC,GF AB N 964del13x2
26 M 26 N HP,AD,CMC,T BB N 964del13 + Un
27 M 26 (sib of 5)e N AD,CMC AB Y 964del13x2
28 M 27 N HP,AD,CMC BB Y 964del13x2
29 M 36 N HP,CMC AA Y R257a + Y90C
30 F 37 N HP,AD,CMC,GF,AS AB Y 964del13 + x10del
31 M 37 N HP,AD,CMC,GF,A BB Un 964del13 + Un
32 M 51 N HP,AD,CMC,K,A AB 0602 964del13x2
33 M 56 N HP,AD,CMC,A AA N 964del13 + R257a
a Y, T1D present; N, T1D absent.
b HP, hypoparathyroidism; AD, Addison’s disease; CMC, chronic mucocutaneous candidiasis; M, malabsorption; K, keratopathy; A, alopecia; 
GF, gonadal failure; H, hepatitis; AS, ankylosing spondylitis; T, hypothyroidism; RCA, red cell aplasia; PA, pernicious anaemia; Ch, cholelithiasis; 
P, pulmonary fibrosis, OC, oral carcinoma; C, cataracts.
c Hph1 genotypes. Allele A is in close to complete linkage disequilibrium with class I INS VNTR alleles, whereas allele B is associated with the class 
III INS VNTR alleles.
d All patients were screened for 964del13 and R257a. Un — second AIRE-1 mutation is currently unknown.
e These patients are deceased.
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patients without T1D were homozygous for the A allele
(OR = 6.4, [5–95% CI = 1.04–38.8]; P = 0.042 Fisher’s
exact test) (Table 2). The two APS1 patients with T1D,
who did not carry the homozygous A allele (subjects 4 and
6), were aged 37 and 24 years, respectively. The mean age
of the subjects with T1D was 29 years (range 10–52) com-
pared to 22.6 years (range 9–56) in the APS1 patients
without T1D. This older age in the T1D group leaves
open the possibility that further cases of T1D may develop
in the unaffected APS1 cohort as they age. In order to
investigate this possibility further, the data were re-
analysed using only those patients without diabetes aged
over 25 years, as it could reasonably be expected that they
would have developed their diabetes by this age. Of these
patients, only two of 10 (20%) without diabetes carried
the homozygous A, T1D susceptible genotype (OR 12
[5–95% CI = 1.29–111.3]; P = 0.03 Fisher’s exact test).
HLA haplotype and diabetes
HLA class II DQB1 typing was performed on 25 patients
with APS1, and two of five with T1D had a ‘non-aspartate
57’ DQB1 allele. Of the 20 APS1 patients without T1D,
seven had a non-aspartate 57 allele (P = 0.6, Fisher’s exact
test). None of the five APS1 patients with diabetes carried
HLA DQΒ*0602, however, four of 20 non-diabetic APS1
patients (20%) did. This difference was not significant
(P = 0.38).
Discussion
Ward et al. (1999) performed INS gene analysis on two
APS1 sibs, who were discordant for T1D. They found that
the sib with T1D was homozygous for a class I INS VNTR
(susceptible) allele, whereas the sib without T1D had a
‘protective’ (heterozygous) INS VNTR genotype (Ward
et al., 1999). This interesting observation led us to exam-
ine the INS genotypes within APS1 subjects from UK.
APS1 is a rare disorder in UK, with an estimated preva-
lence of two to three cases per million, thus this cohort
represents a substantial proportion of all the cases of
APS1 in this population. We found that there is an
increase in the frequency of INS VNTR class I-associated
alleles in those subjects with T1D compared to those with-
out T1D (75% vs. 32%, P = 0.042) in these UK APS1
patients. This suggests an association between the devel-
opment of T1D and homozygosity for class I INS VNTR
in patients with APS1, which is similar to that seen in the
non-APS1 T1D population. This is likely to be an under-
estimate as it is possible that as the patients age, the prev-
alence of diabetes may increase. Indeed, when the data
were re-analysed excluding all patients without diabetes
aged under 25 years, the frequency of INS VNTR class
I-associated alleles in those subjects with T1D compared
to those without T1D is 75% vs. 20% (P = 0.03), i.e.
the association is a little stronger. Previous studies
have shown that 73% of non-APS1 T1D patients are
homozygous for the class I VNTR, this figure is remark-
ably similar to the 75% AA genotype in our APS1 T1D
patients (Bennett et al., 1995). However, our study clearly
demonstrates that INS gene polymorphisms are not
necessary disease alleles for the development of T1D in
our APS1 population. Given the rarity of APS1 and the
subsequent small sample size described here, it is possible
that the results represent a false positive. Although given
the strong biological context of these findings and the con-
cordance between the frequency of AA alleles in this popu-
lation and a non-APS1 population, this may be unlikely.
AIRE is known to be expressed in thymic medullary
epithelial cells, its expression is upregulated in models of
negative selection (Zuklys et al., 2000) and it is required
for the expression of self-antigens including insulin,
within the thymus (Anderson et al., 2002). In addition,
there is differential expression of insulin within the thymus
associated with the different INS VNTR haplotypes.
Homozygosity for class I alleles is associated with low levels
of insulin, but the protective class III allele is associated
with high levels of insulin (Pugliese et al., 1997; Vafiadis
et al., 1997). Positive and negative selection of thymocytes
can be affected by the concentration of peptide presented,
with higher concentration of peptide leading to negative
selection and lower concentrations to positive selection
(Vafiadis et al., 1997). In addition to the effect exerted on
insulin gene expression within the thymus by IDDM2,
recent data from Sabater et al. (2005) reveal that AIRE
has a major effect on thymic insulin expression over and
above that of IDDM2.
In keeping with previous studies, we found no HLA
association (Gylling et al., 2000) in APS1. Gylling et al.
(2000) documented an absence of the protective HLA
DQΒ1*0602 in APS1 patients with diabetes, whereas
APS1 patients without diabetes showed a significant
increase in the prevalence of this haplotype. The results of
our study are entirely consistent with this finding.
To summarize, we have found an association between
insulin gene polymorphisms and the development of T1D
in APS1. These findings suggest that INS gene poly-
morphism, and hence possibly expression of insulin in the
thymus and other immune tissues may still contribute to
diabetes susceptibility, even in the presence of the signifi-
cant AIRE defect in thymic selection.
Table 2. HphI genotypes in APS1 subjects with and without 
type 1 diabetes
APS1 with T1D (%) APS1 without T1D (%)
HphI AAa 6 (75)b 8 (32)
HphI AB or BB 2 (25) 17 (68)
Excluding concordant siblings
HphI AAa 6 (75)c 7 (33)
HphI AB or BB 2 (25) 14 (67)
a AA is equivalent to homozygous class I INS VNTR alleles and is a T1D 
susceptibility genotype in non-APS1 subjects. AB and BB are equivalent 
to a class I/class III heterozygote and class III homozygote (T1D 
protective genotypes), respectively.
b P = 0.042, c P = 0.054, Fisher’s exact test.
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